USPTO Art Unit 1633 Prosecution Statistics

Art Unit Information

Art Unit: 1633
Group: 1630
Tech Center: 1600
Total Cases: 12,235
Last Active: May 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19209618ENHANCED OSTEOINDUCTIVE COMPOSITIONS, SYSTEMS, AND METHODS OF MANUFACTUREMay 2025March 2026Allow1011YesNo
19190623ALGAL BIOFILM HARVESTING METHOD CAPABLE OF REDUCING RELEASE OF PLANKTONIC MICROALGAEApril 2025June 2025Allow200YesNo
19061532EXTRACTION OF ANTIMETHANOGENIC COMPOUNDSFebruary 2025June 2025Allow411YesNo
19044249Epigen AU/11: A NATURAL MATRIX FOR RESTORING HOMEOSTASIS IN CANCER CELL-INFILTRATED TISSUEFebruary 2025July 2025Allow501YesNo
19029962IONIZABLE CATIONIC LIPIDSJanuary 2025August 2025Allow610NoNo
19026966NOVEL AAV CAPSIDS FOR TARGETING NERVOUS SYSTEM AND USES THEREOFJanuary 2025August 2025Allow710YesNo
18990401COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSDecember 2024March 2025Allow300NoNo
18952423VISCOELASTIC HYDROGEL REGULATION OF ORGANOID PATTERNING AND VASCULARIZATIONNovember 2024August 2025Allow911YesNo
18926867STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREONOctober 2024March 2025Allow511YesNo
18882479ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPYSeptember 2024August 2025Allow1120NoNo
18824576DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSSeptember 2024June 2025Allow930YesNo
18824588DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSSeptember 2024December 2024Allow420NoNo
18810714TOPICAL SKIN BALM FOR ANTI-AGING AND HEALING PURPOSESAugust 2024November 2025Abandon1510NoNo
18797392IONIZABLE CATIONIC LIPIDSAugust 2024February 2025Allow710NoNo
18772054PARABURKHOLDERIA SP. AND USE THEREOFJuly 2024July 2025Allow1211YesNo
18752372METHOD FOR SIMPLY CONSTRUCTING TWO-COMPONENT VIRAL VECTOR AND RELATED APPLICATIONS THEREOFJune 2024June 2025Allow1111NoNo
18742810SYSTEMS AND METHODS FOR CONTINUOUS CULTIVATION AND RECOVERY OF COMESTIBLE NON-HUMAN ANIMAL CELLSJune 2024November 2025Allow1731YesNo
18717225MUTANT MYOCILIN DISEASE MODEL AND USES THEREOFJune 2024December 2025Allow1811YesNo
18672959TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USEMay 2024March 2025Allow920NoNo
18672979TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USEMay 2024March 2025Allow920NoNo
18642534COMPOSITIONS AND METHODS RELATING TO POOLED FETAL SUPPORT TISSUEApril 2024November 2025Allow1931YesNo
18640690NUCLEIC ACID ENCODING GENETICALLY ENGINEERED GROWTH FACTOR VARIANTSApril 2024September 2025Abandon1720NoNo
18630620MATERIALS AND METHODS FOR THE MANUFACTURE OF PLURIPOTENT STEM CELLSApril 2024November 2025Allow1910YesNo
18629423ENGINEERED IMMUNE CELLS WITH RECEPTOR CROSS-TALKApril 2024September 2025Allow1820NoNo
18617912CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFMarch 2024February 2025Allow1110YesNo
18602410IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERYMarch 2024January 2026Allow2210NoNo
18591883STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREONFebruary 2024September 2024Allow711YesNo
18590541MEDIUM, METHODS, CELLS AND SECRETED FACTORS FOR STEM CELL CULTURE AND THERAPYFebruary 2024October 2025Allow2010NoNo
18586064ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA AFebruary 2024December 2025Allow2201NoNo
18584039METHOD OF PREPARING A THREE-DIMENSIONAL SCAFFOLD FOR CELL CULTUREFebruary 2024November 2025Allow2130NoNo
18583342ONCOLYTIC ADENOVIRUSES ARMED WITH HETEROLOGOUS GENESFebruary 2024February 2026Allow2401YesNo
18582361COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2024August 2024Allow610NoNo
18582113BIOSYNTHETIC DEVICESFebruary 2024August 2025Abandon1810NoNo
18440821COMPOSITIONS AND METHODS FOR IMPROVING EMBRYO DEVELOPMENTFebruary 2024February 2026Allow2520NoNo
18682853HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLSFebruary 2024May 2025Abandon1620NoNo
18433467TRADITIONAL CHINESE MEDICINE MIXTURE AND TRADITIONAL CHINESE MEDICINE EFFECTIVE INGREDIENT COMPOUND WITH FUNCTION OF PROMOTING DIRECTIONAL DIFFERENTIATION OF STEM CELLS INTO CARDIOMYOCYTES, AND APPLICATIONS THEREOFFebruary 2024October 2024Allow920NoNo
18431504POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOFFebruary 2024September 2024Allow810YesNo
18411647TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENEJanuary 2024March 2025Allow1410NoNo
18397091COMPOSITIONS AND METHODS FOR IN UTERO DELIVERYDecember 2023September 2024Allow820YesNo
18394522HARVESTING CELL-BASED MEATDecember 2023March 2024Allow310NoNo
18391799DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSDecember 2023April 2024Allow410NoNo
18391867RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLSDecember 2023January 2025Abandon1310NoNo
18540309TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPYDecember 2023April 2025Allow1621YesNo
18534335POLYHYDROXYALKANOIC ACID COMPOSITIONS AND METHODS FOR GENERATING SAMEDecember 2023July 2025Allow1911YesNo
18531157Parallel Cell Processing Method and FacilityDecember 2023June 2025Allow1821YesNo
18510460ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPYNovember 2023January 2025Abandon1420NoNo
18560712Mesenchymal Stem Cells for Use in the Treatment of Skin DefectsNovember 2023March 2026Allow2800YesNo
18387555XENOTRANSPLANTATION PRODUCTS AND METHODSNovember 2023June 2025Allow1910NoNo
18501227APPLICATION OF ANTARCTIC RED PIGMENT IN PREPARATION OF DRUGS FOR TREATMENT AND PREVENTION OF HYPERURICEMNovember 2023February 2026Abandon2840YesNo
18382284COMPOSITIONS AND METHODS FOR TREATING CANCEROctober 2023January 2025Allow1520YesNo
18484008Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injuryOctober 2023October 2025Abandon2511NoNo
18376832Carbon Capture by Algal Inoculation of Ocean Ice and/or Sea IceOctober 2023June 2025Allow2001YesNo
18376827MATERIALS AND METHODS FOR ALGAL INOCULATION TO EFFECT DIRECT CAPTURE OF CARBON DIOXIDE FROM AIROctober 2023June 2025Allow2001YesNo
18480890METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATIONOctober 2023January 2025Allow1501NoNo
18371959TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USESeptember 2023July 2024Allow1020YesNo
18470861Expanding Cells In A BioreactorSeptember 2023March 2025Allow1810NoNo
18463155TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIESSeptember 2023January 2026Abandon2810NoNo
18239216INJECTABLE HYDROGEL FOR TREATMENT OF SEGMENTAL BONE DEFECTAugust 2023December 2024Allow1611NoNo
18454288Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune DisordersAugust 2023August 2024Allow1100NoNo
18447651COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA)August 2023February 2024Allow700NoNo
18361233CELL CULTURE MEDIUMJuly 2023May 2025Abandon2220YesNo
18352386THRAUSTOCHYTRIDS, FATTY ACID COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOFJuly 2023May 2025Allow2221YesNo
18351804WET PRESERVATION OF TISSUEJuly 2023April 2025Allow2120YesNo
183514883-DIMENSIONAL (3D) TISSUE-ENGINEERED MUSCLE FOR TISSUE RESTORATIONJuly 2023April 2025Allow2111NoNo
18218896METHOD AND DEVICE FOR TARGET CELL SEPARATIONJuly 2023November 2025Allow2931NoNo
18347142COMPOSITION FOR CULTURING BRAIN ORGANOID BASED ON DECELLULARIZED BRAIN MATRIX AND METHOD FOR PREPARING SAMEJuly 2023February 2026Allow3130NoNo
18347009NON-HUMAN ANIMALS COMPRISING A HUMANIZED COAGULATION FACTOR 12 LOCUSJuly 2023September 2024Allow1400NoNo
18327728POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIAJune 2023February 2026Allow3310NoNo
18322961ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSIONMay 2023December 2023Allow710NoNo
18321701COMPOSITION AND METHODS FOR HAIR REGROWTHMay 2023March 2026Abandon3301NoNo
18319679TRANSCRIPTION FACTORS CONTROLLING DIFFERENTIATION OF STEM CELLSMay 2023January 2026Abandon3211NoNo
18314451Expanding Cells In A BioreactorMay 2023November 2025Allow3010YesNo
18313126METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATIONMay 2023February 2026Allow3340NoNo
18034564HYDROGEL STRUCTURE, METHOD FOR PRODUCING HYDROGEL STRUCTURE, AGENT, AND TRANSPLANTATION METHODApril 2023March 2026Abandon3501NoNo
18140279METHODS FOR CULTURING HUMAN KERATINOCYTESApril 2023September 2025Abandon2901NoNo
18306673Tracking and Manipulating Cellular RNA via Nuclear Delivery of CRISPR/CAS9April 2023September 2025Abandon2811NoNo
18033756METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE DISEASE WITH IPSC-INDUCED HUMAN SKELETAL MUSCLE STEM CELLSApril 2023March 2026Allow3510YesNo
18306152MICROBEADS FOR CELL CULTURE AND METHOD OF MONITORING CELL CULTURE USING THE SAMEApril 2023May 2025Allow2510NoNo
18136660INDUCIBLE PROMOTERSApril 2023April 2025Allow2411NoNo
18133843ENCAPSULATED CELLS AND METHODS OF PRESERVING THEREOFApril 2023March 2026Abandon3510NoNo
18030592COMPOSITION FOR PROMOTING HAIR GROWTH AND/OR INHIBITING HAIR LOSSApril 2023February 2026Abandon3410NoNo
18191718COMPOSITION TO INCREASE CELLULARLONGEVITYMarch 2023March 2025Abandon2331NoNo
18188326T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONSMarch 2023September 2023Allow610NoNo
18124741METHOD FOR DECELLULARIZATION OF SKIN TISSUE, METHOD FOR CONSTRUCTION OF ARTIFICIAL SKIN, METHOD FOR PREPARATION OF HYDROGEL OF DECELLULARIZED SKIN TISSUE, LYOPHILIZED, DECELLULARIZED SKIN TISSUE, AND BIOINKMarch 2023December 2025Abandon3311NoNo
18117915Devices And Methods For Mitochondria Replacement And For Generating Cellular TherapeuticsMarch 2023February 2026Allow3511NoNo
18172670METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINSFebruary 2023October 2023Allow810NoNo
18112239METHODS FOR ANALYSIS OF SOMATIC MOBILE ELEMENTS, AND USES THEREOFFebruary 2023January 2026Abandon3511NoNo
18166627AMNIOTIC CYTOKINE FORMULATIONSFebruary 2023February 2025Abandon2420NoYes
18105374Oncolytic Immunotherapy by Tumor Micro-Environment RemodelingFebruary 2023May 2025Allow2740NoNo
18164308Methods For Development And Use Of Minimally Polarized Function Cell Micro-Aggregate Units In Tissue Applications Using LGR4, LGR5, And LGR6 Expressing Epithelial Stem CellsFebruary 2023July 2025Allow2920NoNo
18162104WT1 VACCINEJanuary 2023February 2026Allow3730NoNo
18100195Differentiation MethodJanuary 2023October 2025Allow3320YesNo
18156887Pocket Engineering of HLA Alleles for Treating AutoimmunityJanuary 2023June 2025Allow2921YesNo
18156378CELL SEPARATION APPARATUS AND METHODS OF USEJanuary 2023October 2025Abandon3320NoNo
18005612TROPHIN GENOME EDITING FOR TREATING DUCHENNE MUSCULAR DYSTROPHY (DMD)January 2023March 2026Allow3810NoNo
18152470IN VITRO METHOD FOR CREATING A VIABLE CONNECTIVE TISSUE AND/OR OSSEOUS TISSUEJanuary 2023December 2024Allow2310NoNo
18093805COMPOSITIONS COMPRISING ALPHA-FACTOR PREPRO SEQUENCE AND USES THEREOFJanuary 2023September 2025Allow3331YesNo
18003067THREE-DIMENSIONAL BIOMIMETIC CHIP FOR SIMULATING ENDOMETRIUM, AND ENDOMETRIUM SIMULATING METHOD USING SAMEDecember 2022February 2025Allow2620NoNo
18083019Compositions and Manufacture of Allograft TissueDecember 2022November 2023Allow1111YesNo
18066420PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOFDecember 2022July 2023Allow710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1633.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
274
Examiner Affirmed
195
(71.2%)
Examiner Reversed
79
(28.8%)
Reversal Percentile
30.7%
Lower than average

What This Means

With a 28.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1863
Allowed After Appeal Filing
238
(12.8%)
Not Allowed After Appeal Filing
1625
(87.2%)
Filing Benefit Percentile
0.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1633 - Prosecution Statistics Summary

Executive Summary

Art Unit 1633 is part of Group 1630 in Technology Center 1600. This art unit has examined 12,235 patent applications in our dataset, with an overall allowance rate of 43.7%. Applications typically reach final disposition in approximately 39 months.

Comparative Analysis

Art Unit 1633's allowance rate of 43.7% places it in the 4% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1633 receive an average of 2.41 office actions before reaching final disposition (in the 84% percentile). The median prosecution time is 39 months (in the 16% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.